Is TRT safe for your heart? Here's the actual trial.
TRAVERSE directly answers the #1 fear-based search query in this category with a large, rigorous randomized trial, not vague marketing reassurance. Here's exactly what it found, alongside what testosterone does and doesn't do for function and cognition.
The trial landscape
| Trial | N | Duration | Headline result | Source |
|---|---|---|---|---|
| TRAVERSE | 5,246 | Mean 21.7 months treatment, ~33 months follow-up | MACE in 7.0% (testosterone) vs. 7.3% (placebo); HR 0.96 (95% CI 0.78-1.17), noninferior. Secondary: higher AFib (3.5% vs 2.4%) and VTE (1.7% vs 1.2%). | Lincoff 2023 |
| T Trials | 788 | 1 year | Improved sexual function, mood, bone density; no meaningful improvement in energy/vitality; no cognitive benefit (confirmed in a companion Cognitive Function Trial). | Snyder 2016 |
What this means in plain language
The heart-safety fear is largely resolved, with real caveats
TRAVERSE is a large, rigorous, purpose-built cardiovascular-safety trial: exactly the kind of evidence vague provider marketing usually can't point to. It found testosterone therapy noninferior to placebo on the composite of cardiovascular death, heart attack, and stroke. But it also found more atrial fibrillation and blood clots on testosterone: a legitimate reason for ongoing monitoring, not something to omit for a cleaner marketing story.
TRT is not a cognition or energy drug
The T Trials found real, modest benefits (sexual function, mood, bone density) but no meaningful improvement in energy or cognition. If a provider's marketing leans on "mental clarity" or "vitality" claims beyond that, the trial evidence doesn't support it as strongly as the sexual-function and bone-density findings do.
"Hypogonadism" and "Low T" are not the same word
Every provider studied in TRAVERSE and the T Trials had lab-confirmed low testosterone plus symptoms: a diagnosed condition. "Low T" as used in marketing is a symptom-based sales term with no lab requirement behind it. This distinction is why lab-testing-before-prescribing is the single clearest quality signal when choosing a provider.
Decision framework
| Your priority | What the evidence supports |
|---|---|
| Confirming you actually have low T | Requires bloodwork: a provider that skips this is prescribing outside what any trial evidence actually studied. |
| Cardiovascular safety concerns | TRAVERSE is the trial to cite directly: noninferior on MACE, though AFib/VTE risk was elevated and worth monitoring. |
| Format preference (injection vs. gel) | No major efficacy difference in trials: mostly a convenience/adherence choice. |
| Expecting a cognition or energy boost | Trial evidence doesn't support this as a primary benefit: sexual function, mood, and bone density are the better-supported outcomes. |
Sources
- Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023.
- Snyder PJ, et al. Effects of Testosterone Treatment in Older Men (T Trials). N Engl J Med. 2016.
- National Institute on Aging: NIH-Supported Trials of Testosterone Therapy Report Mixed Results
- Alzforum: Case Closed: Testosterone Does Not Boost Cognition
See how 9 providers score
Every provider scored on whether they require lab-confirmed diagnosis, plus rating, pricing, and support.
View the scores